Using Metoprolol in Cardiac Patients with COPD

Safety and Efficacy

• The European Society of Cardiology recommends that beta-blockers with documented effects on morbidity and mortality, such as metoprolol, are used in patients with cardiac conditions even when they have co-existing COPD 1, 2, 3
• The majority of patients with heart failure and COPD can safely tolerate beta-blocker therapy without significant deterioration in pulmonary function 2

Dosing Protocol

• The initial dosing of metoprolol tartrate should be 25-50 mg twice daily or metoprolol succinate (extended-release) 50 mg once daily, with gradual up-titration every 2-4 weeks if no signs of worsening COPD or heart failure occur 4, 5
• The target dose of metoprolol tartrate is up to 200 mg daily or metoprolol succinate up to 200 mg once daily 5, 4

Monitoring

• Patients should be monitored for signs of worsening heart failure, bronchospasm, or respiratory symptoms during initiation and titration of metoprolol therapy 2
• Blood pressure and heart rate should be monitored at each visit, with a target resting heart rate of 50-60 beats per minute unless limiting side effects occur 4

Important Precautions

• If severe respiratory deterioration occurs, the dose of metoprolol should be reduced rather than discontinued completely 6, 5
• Metoprolol therapy should not be abruptly discontinued in patients with coronary artery disease, and if necessary, the dose should be gradually reduced over 1-2 weeks 4

Special Considerations

• Asthma remains an absolute contraindication to beta-blocker therapy, but COPD is not a contraindication 7, 2
• For patients with both heart failure and COPD experiencing an exacerbation, temporary reduction in beta-blocker dose may be necessary, but complete discontinuation should be avoided if possible 7, 6

Cardiovascular Management in COPD Patients

Mortality and Morbidity Benefits

• Cardioselective beta-blockers, such as metoprolol, reduce mortality in COPD patients undergoing vascular surgery, according to the European Heart Journal 8
• The European Society of Cardiology recommends that beta-blockers, including metoprolol, be used in COPD patients with cardiovascular disease, as the survival benefit outweighs potential respiratory risks 8

Practical Prescribing Algorithm

• The European Heart Journal suggests starting beta-blocker therapy outside of COPD exacerbations when the patient is stable, and initiating optimally between 30 days and at least 1 week before surgery 8
• Target resting heart rate of 50-60 beats per minute (or 60-70 bpm perioperatively) when using beta-blockers like metoprolol, as recommended by the European Heart Journal 8

Monitoring Requirements

• Monitor heart rate and blood pressure in patients with COPD taking metoprolol, as recommended by the European Heart Journal 8

Inappropriate Withholding

• The European Heart Journal advises against withholding beta-blockers in COPD patients with documented cardiovascular disease based solely on the presence of COPD 8
• Beta-blockers, including metoprolol, are not contraindicated in patients with intermittent claudication, according to the European Heart Journal 8

Bisoprolol Use in COPD Patients

Introduction to Bisoprolol in COPD

• The American Heart Association recommends that bisoprolol is not contraindicated in patients with COPD, particularly when there is a compelling cardiovascular indication such as heart failure, post-myocardial infarction, or coronary artery disease 9, 10

Key Distinction: COPD vs. Asthma

• The British Thoracic Society guidelines state that COPD is a relative contraindication to beta-blocker therapy, not an absolute one, and the decision depends on the presence of cardiovascular disease and the balance of risks versus benefits 9, 11
• Asthma is an absolute contraindication to beta-blocker therapy and should never receive these agents 9

Cardiovascular Indications for Bisoprolol

• The American College of Cardiology recommends that beta-1 selective agents like bisoprolol reduce all-cause and in-hospital mortality in COPD patients with cardiovascular disease, including heart failure with reduced ejection fraction, post-myocardial infarction, and coronary artery disease 9, 10

Preferred Beta-Blockers in COPD

• The European Society of Cardiology recommends that bisoprolol is preferred over non-selective beta-blockers in COPD patients due to its beta-1 selectivity 9
• Cardioselective agents, such as bisoprolol and metoprolol, have less effect on bronchial beta-2 receptors and are equally preferred for COPD patients with cardiovascular indications 9

Beta-Blockers in COPD: Evidence-Based Recommendations

Introduction to Beta-Blocker Use in COPD

• The American Journal of Respiratory and Critical Care Medicine recommends the use of selective beta-1 blockers in patients with heart failure with reduced ejection fraction and COPD, as it improves survival 12
• Beta-blocking eye drops should be avoided in patients with COPD, as recommended by Thorax 13

Special Populations

• The American Journal of Respiratory and Critical Care Medicine recommends treatment with selective beta-1 blockers in patients with heart failure and COPD, as it improves survival, and notes that the prevalence of heart failure in COPD patients ranges from 20-70% 12